Mannelli G, Magnelli L, Deganello A, Busoni M, Meccariello G, Parrinello G, Gallo O
First Clinic of Otorhinolaryngology Head and Neck Surgery, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.
Department of Sperimental Pathology and Oncology Medical School, University of Florence, Florence, Italy.
Clin Otolaryngol. 2015 Aug;40(4):312-20. doi: 10.1111/coa.12368.
Investigators hypothesized that cancer stem cells (CSCs) could play a role in determining cancer progression by metastasizing to cervical lymph node (N+) and then influencing prognosis of head and neck squamous cell carcinomas (HNSCCs) patients.
To identify CSCs in HNSCCs and their clonogenic capacity.
In vitro study.
Putative CSCs from 29 primary HNSCCs and 19 corresponding node metastases were analyzed.
Immunohistochemical (IHC) was performed, and CSCs' clonogenic in vitro capacity was tested; ones epithelial nature of cancer cells forming colonies was confirmed by a second IHC, fluorescence-activated cell sorting (FACS) analysis helped in counting CD44/CD133-CSCs markers percentage expression in HNSCC tumour-derived cultures.
Immunohistochemical showed CD44 (93.1%) and CD133 (10.34%) expression; FACS-analysis showed the enrichment of CD44/CD133 cancer cells, with the highest clonogenic capacity of CD44+-subpopulation; a higher CD44 rates were documented from N+ subcultures than from original tumours (P < 0.05).
A putative cancer stem-like cell population is detectable in HNSCCs, and our findings show their in vitro clonogenic capacity by demonstrating that CD44+-cultured cells are the main population proliferating obtained by N+ HNSCC metastases, emphasizing their possible role in tumour progression.
研究人员推测癌症干细胞(CSCs)可能通过转移至颈部淋巴结(N+)进而影响头颈部鳞状细胞癌(HNSCCs)患者的预后,在决定癌症进展过程中发挥作用。
鉴定HNSCCs中的CSCs及其克隆形成能力。
体外研究。
分析了来自29例原发性HNSCCs及19例相应淋巴结转移灶中的假定CSCs。
进行免疫组织化学(IHC)检测,并测试CSCs的体外克隆形成能力;通过第二次IHC证实形成集落的癌细胞的上皮性质,荧光激活细胞分选(FACS)分析有助于计数HNSCC肿瘤来源培养物中CD44/CD133-CSCs标志物的表达百分比。
免疫组织化学显示CD44(93.1%)和CD133(10.34%)表达;FACS分析显示CD44/CD133癌细胞富集,其中CD44+亚群的克隆形成能力最高;N+亚培养物中的CD44率高于原发肿瘤(P < 0.05)。
在HNSCCs中可检测到假定的癌症干细胞样细胞群,我们的研究结果通过证明CD44+培养细胞是N+ HNSCC转移获得的主要增殖细胞群,显示了它们的体外克隆形成能力,强调了它们在肿瘤进展中的可能作用。